Intratumoral plasma cells: More than a predictive marker of response to anti-PD-L1 treatment in lung cancer?

Jean-Luc Teillaud; Marie-Caroline Dieu-Nosjean

doi:10.1016/j.ccell.2022.02.008

Intratumoral plasma cells: More than a predictive marker of response to anti-PD-L1 treatment in lung cancer?

Cancer Cell. 2022 Mar 14;40(3):240-243. doi: 10.1016/j.ccell.2022.02.008. Epub 2022 Feb 24.

Authors

Jean-Luc Teillaud¹, Marie-Caroline Dieu-Nosjean²

Affiliations

¹ Sorbonne Université, UMRS 1135, Faculté de Médecine Sorbonne Université, Paris, France; INSERM U1135, Faculté de Médecine Sorbonne Université, Paris, France; Laboratory "Immune microenvironment and immunotherapy," Centre of Immunology and Microbial Infections-Paris (CIMI-Paris), Paris, France.
² Sorbonne Université, UMRS 1135, Faculté de Médecine Sorbonne Université, Paris, France; INSERM U1135, Faculté de Médecine Sorbonne Université, Paris, France; Laboratory "Immune microenvironment and immunotherapy," Centre of Immunology and Microbial Infections-Paris (CIMI-Paris), Paris, France. Electronic address: marie-caroline.dieu-nosjean@inserm.fr.

PMID: 35216677
DOI: 10.1016/j.ccell.2022.02.008

Abstract

In this issue of Cancer Cell, Patil et al. report that increased plasma cell signatures are predictive of an extended overall survival in non-small-cell lung cancer patients treated with a PD-L1 inhibitor and that these cells are associated with the presence of tertiary lymphoid structures.

Publication types

Comment

MeSH terms

B7-H1 Antigen / therapeutic use
Carcinoma, Non-Small-Cell Lung* / drug therapy
Carcinoma, Non-Small-Cell Lung* / mortality
Humans
Immune Checkpoint Inhibitors
Lung Neoplasms* / drug therapy
Lung Neoplasms* / mortality
Plasma Cells

Substances

B7-H1 Antigen
Immune Checkpoint Inhibitors